Update on the acute treatment of hereditary angioedema.
Hereditary angioedema (HAE) is a genetic autosomal dominant condition caused by C1-esterase inhibitor protein (C1INH) deficiency that results in episodic tissue angioedema. Recently, new therapies have been developed to more effectively manage this rare but serious condition. This review will provide a concise summary of HAE acute treatment options for the practicing allergist/immunologist. Clinical study data for emerging HAE therapies were reviewed and summarized. Based on efficacy and safety data from completed clinical studies, three new HAE treatments have recently been approved by the Food and Drug Administration: nanofiltered plasma-derived C1INH for prophylactic therapy, pasteurized plasma-derived C1INH for acute therapy, and ecallantide for acute therapy. Two other promising therapies, recombinant C1INH and icatibant, are in various stages of the U.S. regulatory process. The medical management of HAE is entering a new era with the availability of safe, effective condition-specific treatments. Clinicians should consider a number of patient- and medication-specific factors when designing individualized treatment plans for HAE patients.
Department of Medicine, University of California-Los Angeles, 90095, USA. mriedl@mednet.ucla.edu
Marc A
MA
Riedl
D054179:Angioedemas, Hereditary / Q000188:drug therapy*; D001920:Bradykinin / Q000031:analogs & derivatives / Q000627:therapeutic use; D050718:Complement C1 Inhibitor Protein / Q000627:therapeutic use; D006801:Humans; D010455:Peptides / Q000627:therapeutic use; D016896:Treatment Outcome
D050718:Complement C1 Inhibitor Protein; D010455:Peptides; C511194:ecallantide; C065679:icatibant; D001920:Bradykinin